by: Parent Project Muscular Dystrophy
Dyne Therapeutics recently joined PPMD for a community webinar on the DELIVER clinical trial evaluating DYNE-251. The Dyne team provided the latest updates on the Phase 1/2 global DELIVER study of the company’s investigational therapy for individuals living with Duchenne who are amenable to exon 51 skipping.
